StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.85+0.02 (+0.41%)

Close on Nov 16, 2026Market cap $801.41MP/E 6.3Yield –

Ironwood Pharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Ironwood Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was 60.1%. For fiscal 2025 it was 33.3%, against 26.5% the year before. The highest annual figure on record is 61.0% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202533.3%+6.8
FY2024Dec 31, 202426.5%+240.0
FY2023Dec 31, 2023-213.5%−274.5
FY2022Dec 31, 202261.0%+4.8
FY2021Dec 31, 202156.1%+19.4
FY2020Dec 31, 202036.7%+8.7
FY2019Dec 31, 201928.0%+71.5
FY2018Dec 31, 2018-43.5%−38.3
FY2017Dec 31, 2017-5.2%+13.8
FY2016Dec 31, 2016-18.9%+49.3
FY2015Dec 31, 2015-68.3%+153.3
FY2014Dec 31, 2014-221.6%+879.8
FY2013Dec 31, 2013-1101.4%−1052.9
FY2012Dec 31, 2012-48.4%+52.0
FY2011Dec 31, 2011-100.4%+38.1
FY2010Dec 31, 2010-138.6%+38.6
FY2009Dec 31, 2009-177.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202670.2%+17.0
Q1 FY2026Mar 31, 202668.1%+138.9
Q4 FY2025Dec 31, 202514.3%−20.5
Q3 FY2025Sep 30, 202561.8%+33.9
Q2 FY2025Jun 30, 202553.2%+26.7
Q1 FY2025Mar 31, 2025-70.7%−85.5
Q4 FY2024Dec 31, 202434.8%+2.8
Q3 FY2024Sep 30, 202428.0%−7.2
Q2 FY2024Jun 30, 202426.5%+1035.1
Q1 FY2024Mar 31, 202414.7%−43.0
Q4 FY2023Dec 31, 202332.0%−31.8
Q3 FY2023Sep 30, 202335.2%−27.8
Q2 FY2023Jun 30, 2023-1008.7%−1065.9
Q1 FY2023Mar 31, 202357.8%−1.6
Q4 FY2022Dec 31, 202263.8%+15.5
Q3 FY2022Sep 30, 202263.0%+0.2
Q2 FY2022Jun 30, 202257.2%−5.3
Q1 FY2022Mar 31, 202259.3%+8.2
Q4 FY2021Dec 31, 202148.3%+4.3
Q3 FY2021Sep 30, 202162.8%+18.7
Q2 FY2021Jun 30, 202162.6%+26.0
Q1 FY2021Mar 31, 202151.1%+34.6
Q4 FY2020Dec 31, 202044.0%+4.8
Q3 FY2020Sep 30, 202044.1%−6.1
Q2 FY2020Jun 30, 202036.6%+15.5
Q1 FY2020Mar 31, 202016.5%+41.2
Q4 FY2019Dec 31, 201939.3%+16.4
Q3 FY2019Sep 30, 201950.2%+273.4
Q2 FY2019Jun 30, 201921.1%+39.2
Q1 FY2019Mar 31, 2019-24.6%+27.2
Q4 FY2018Dec 31, 201822.8%−67.2
Q3 FY2018Sep 30, 2018-223.1%−200.8
Q2 FY2018Jun 30, 2018-18.1%+44.9
Q1 FY2018Mar 31, 2018-51.9%+24.2
Q4 FY2017Dec 31, 201790.0%+97.2
Q3 FY2017Sep 30, 2017-22.4%+20.4
Q2 FY2017Jun 30, 2017-63.0%–
Q1 FY2017Mar 31, 2017-76.1%–
Q4 FY2016Dec 31, 2016-7.2%–
Q3 FY2016Sep 30, 2016-42.8%–

More Ironwood Pharmaceuticals figures

See a number that looks wrong?